Accrua by Deep Longevity uses an AI model to identify 'fast agers' via blood tests and directs them to GLP-1 treatments. The US telehealth platform is scheduled to launch in October 2026.
Accrua by Deep Longevity uses an AI model to identify 'fast agers' via blood tests and directs them to GLP-1 treatments. The US telehealth platform is scheduled to launch in October 2026.